Treatments received for incident RA were available in 505 women (72.3%): 429 RA women received methotrexate (85%), 88 had a TNFα inhibitor (17.4%), and 39 (7.7%) other biologics (rituximab, abatacept, tocilizumab). This evidence concerns the gene TNF and rheumatoid arthritis.